A phase II trial of calcitriol and naproxen in recurrent prostate cancer

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3605-3610

  Srinivas, Sandy ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitriol; Non steroids; Prostate cancer

Indexed keywords

CALCITRIOL; NAPROXEN; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL CRAMP; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NEPHROLITHIASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCITRIOL; HUMANS; MALE; MIDDLE AGED; NAPROXEN; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 68549101673     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Feldman D, Malloy P, Krishnan AV and Balint E: Vitamin D: biology action and clinical implications. In: Marcus R, Feldman D, Nelson D and Rosen C (eds.). Osteoporosis. 3rd ed. San Diego: Elsevier/Academic Press pp. 317-382, 2007.
2. Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700, 2007.
3. Krishnan AV, Moreno J, Nonn L, Malloy PJ, Swami S, Peng L, Peehl DM and Feldman D: Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 103: 694-702, 2007. (Pubitemid 46401340)
4. Badawi AF: The role of prostaglandin synthesis in prostate cancer. BJU Int 85: 451-462, 2000. (Pubitemid 30142622)
5. Hussain T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125-135, 2003.
6. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM and Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65: 7917-7925, 2005. (Pubitemid 41297270)
7. De Marzo AM, Nakai Y and Nelson WG: Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 25: 398-400, 2007.
8. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB and Lokeshwar BL: Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119: 1082-1087, 2006. (Pubitemid 44116917)
9. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78, 2000. (Pubitemid 30004877)
10. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S and Llombart-Bosch A: Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 48: 745-751, 2005. (Pubitemid 41495372)
11. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, HIa T and Wada S: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596, 2000.
12. Tong M and Tai HH: Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 276: 77-81, 2000.
13. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818-7823, 2006. (Pubitemid 44289243)
14. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004. (Pubitemid 39657428)
15. Breyer RM, Bagdassarian CK, Myers SA and Breyer MD: Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
16. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM and Feldman D: Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59: 243-251, 2004. (Pubitemid 38509756)
17. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD and Feldman D: Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92: 131-141, 2004. (Pubitemid 39535854)
18. Markowitz SD: Aspirin and colon cancer - targeting prevention? N Engl J Med 356: 2195-2198, 2007.
19. Topol EJ: Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 351: 1707-1709, 2004. (Pubitemid 39383201)
20. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK and Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-8, 2 p following 8, 2000.
21. Beer TM: Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol Oncol 21: 399-405, 2003.
22. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A and Clow FW: Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25: 669-674, 2007. (Pubitemid 350002922)
23. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C and Soule HR: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22: 537-556, 2004. (Pubitemid 41079783)
24. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 163: 1632-1642, 2000. (Pubitemid 30366704)
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
26. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001. (Pubitemid 33741879)
27. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A and Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171: 1141-1147, 2004. (Pubitemid 38327544)
28. Sprenkle PC and Fisch H: Pathologic effects of testosterone deprivation. Curr Opin Urol 17: 424-430, 2007.
29. 3 (calcitriol). J Urol 159: 2035-2039; discussion 9-40, 1998. (Pubitemid 29190750)
30. Osborn JL, Schwartz GG, Smith DC, Gahnson R, Day R and Trump DL: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195, 1995.
31. 3) and dexamethasone in androgen-independent prostate cancer. Cancer 106: 2136-2142, 2006. (Pubitemid 43673234)
32. Beer TM, Lemmon D, Lowe BA and Henner WD: High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97: 1217-1224, 2003. (Pubitemid 36237307)
33. Beer TM, Venner PM, Ryan CW, Pettrylak DP, Chatta G, Dean Ruether J, Chi KN, Cur JE and DeLoughery TG: High-dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 135: 392-394, 2006. (Pubitemid 44484849)
34. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
35. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
36. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C and Wallen E: Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12: 2172-2177, 2006.
37. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ and Kantoff PW: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24: 2723-2728, 2006. (Pubitemid 46630568)